Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

95 results about "Human lung" patented technology

The human lungs are the organs of respiration. Humans have two lungs, a right lung and a left lung. The right lung consists of three lobes while the left lung is slightly smaller consisting of only two lobes. Together, the lungs contain approximately 2,400 kilometres of airways and 300 to 500 million alveoli. Estimates of the total surface area of lungs vary from 30-50 square metres up to 70-100 square metres in adults — which might be roughly the same area as one side of a tennis court. However, such estimates may be of limited use unless qualified by a statement of scale at which they are taken. Furthermore, if all of the capillaries that surround the alveoli were unwound and laid end to end, they would extend for about 992 kilometres. The lungs together weigh approximately 1.3 kilograms, with the right lung weighing more than the left. The pleural cavity is the potential space between the two serous membranes, of the lungs; the parietal pleura, lining the inner wall of the thoracic cage, and the visceral pleura, lining the organs themselves–the lungs. The respiratory system includes the conducting zone, which is part of the respiratory tract, that conducts air into the lungs.

Collection, assessment and early detection of human lung cancer biomarkers in exhaled breath condensates of mouse animal models

PendingUS20240410022A1Microbiological testing/measurementSensorsHeterograftsTransgene
The present disclosure provides a single mouse exhaled breath collection device and proof-of-concept analyses utilizing an ultra-sensitive and customizable EV purification assay, EV-CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.
Owner:HACKENSACK MERIDIAN HEALTH INC

Pleura cavity simulation device

The utility model discloses a pleural cavity simulation device. The pleural cavity simulation device comprises a negative pressure ball, the negative pressure ball comprises a ball body used for simulating the chest of the human body and an expandable balloon used for simulating the lung of the human body, the balloon is placed in the ball body, a first ventilation opening is formed in the air inlet end of the balloon, one end of the first ventilation opening is communicated with the balloon, and the other end of the first ventilation opening is communicated with the balloon. The other end of the first ventilation opening penetrates out of the ball body, a second ventilation opening is formed in the lower end of the ball body and communicated with the ball body, the balloon is communicated with the outside atmosphere through the first ventilation opening, and the ball body is communicated with the outside atmosphere through the second ventilation opening. And switches are arranged on the first air vent and the second air vent. The device has the advantages that the structure is simple, and the negative pressure structure of the pleural cavity and the pneumothorax state can be truly simulated.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

Collection, assessment and early detection of human lung cancer biomarkers in exhaled breath condensates of mouse animal models

PCT designated stage expiredWO2025019709A2Component separationMicrobiological testing/measurementHeterograftsTransgene
The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.
Owner:HACKENSACK MERIDIAN HEALTH INC

Drug testing platform for simulating lung environment

A drug testing platform for simulating a lung environment includes a microfluidic chip and a stretching device. The microfluidic chip defines a microfluidic channel structure. The microfluidic channel structure includes a test unit, a cell shunt unit and a drug shunt unit. The stretching device is configured to stretch and contract the test unit in a manner of a reciprocal motion, thereby making degree of deformation of a plurality of test area of the test unit to be same during the reciprocal motion. The drug testing platform for simulating the lung environment according to the present disclosure may configure an environment that simulates a breathing motion of a human lung, and obtain multiple results within a single test.
Owner:NATIONAL TSING HUA UNIVERSITY

Polysaccharide with antioxidant activity, cytotoxic activity against different types of cancer cells, and healing activity

PCT designated stageWO2026152242A1Cancer cellCancer drugs
The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and / or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.
Owner:UNIV DE MAGALLANES +2

Generation of lung organoids from pluripotent stem cells and use thereof

Disclosed herein are lung progenitor cells that are in the form of lung organoids and methods of generating the lung progenitor cells. The lung organoids can be an important resource for treating lung disorders and injuries, studies in human lung regeneration, disease modeling, and drug target identification and validation.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Intelligent scoring system for making human lung and external gas exchange model experiment

The invention discloses an intelligent scoring system for an experiment of making a human lung and external gas exchange model, and the system comprises a hardware module which is composed of a student tablet with a camera and a server with high computing power. The student tablet portion with the camera is composed of a camera unit, an interactive touch input unit and a display unit, and the server portion is composed of an image decoding unit, a deep network unit, a logic analysis unit and an image coding unit. According to the intelligent scoring system for making the human lung and external gas exchange model experiment, YOLO has the characteristics of being fine, small and rapid, the time for service logic codes of the human lung model experiment is very short, the scoring condition of experiment operation can be directly given in real time in the experiment process of students, and the experiment efficiency is improved. And the human lung model experiment is used as a part of the physical and chemical student experiment, so that the integrity of intelligent scoring of the physical and chemical student experiment is also improved.
Owner:SHENZHEN HOPESEN TECH CO LTD

Biodegradable lung sealants

PendingUS20260183331A1High molecular massBiochemistry
The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
Owner:ETHICON INC

Construction method and application of human lung 3D cell microspheres and human pulmonary fibrosis 3D organoid

The invention discloses a construction method and application of a human lung 3D cell microsphere and a human pulmonary fibrosis 3D organoid. The construction of the human lung 3D cell microspheres comprises the following steps: respectively digesting human primary fibrosis cells and human II-type alveolar epithelial cells which are subjected to adherent culture into single cells; mixing digested human primary fibrotic cells, human II-type alveolar epithelial cells and THP-1 macrophages subjected to suspension culture according to a cell number ratio of 1: 1: 1, so as to obtain a cell precipitate; and preparing the cell precipitate into cell matrigel microspheres by using a T-type microfluidic technology, and culturing to obtain the human lung 3D cell microspheres. And further inducing the human lung 3D cell microspheres by using a human lung organoid culture medium containing 50ng / mL of TGF-beta for 24-48 hours to obtain the human pulmonary fibrosis 3D organoid. According to the invention, 3D cell microspheres with human normal lung cell characteristics and protein expression can be formed within 3 days, and pulmonary fibrosis 3D organs can be obtained after short-time induction.
Owner:SHENZHEN SIGNOR BIOTECHNOLOGY CO LTD

Lung-kidney interaction simulation system based on organ chip

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Pulmonary function tester (for respiratory medicine only)

1. The name of the product of this design: Pulmonary function tester (for respiratory medicine only). 2. Purpose of the product of this design: medical equipment used to check and detect the functioning of human lungs. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.
Owner:THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIV

Novel compound and pharmaceutical composition comprising same as active ingredient

The present invention relates to a novel compound which modulates the function and differentiation of a cytoskeleton involved in pulmonary fibrosis and thus can be used for preparing a medicament capable of treating related diseases. It has been determined that: the novel compound according to the present invention or a pharmaceutically acceptable salt thereof has an effect of modulating actin polymerization required for cytoskeleton formation; and the expression of alpha-SMA and F-actin, which are main factors causing fibrosis, is effectively inhibited in human lung tissue-derived fibroblasts (MRC5). Furthermore, it has been determined that when activated macrophages are treated with the compounds, the level of inflammation of inflammatory cytokines caused by the macrophages is reduced. Therefore, the novel compound according to the present invention is expected to be effectively used in the prevention and treatment of diseases associated with pulmonary fibrosis as a preparation having an effect of inhibiting or reducing pulmonary fibrosis.
Owner:SAPIENS BIOTECHNOLOGY CO LTD

Inhibitor of the flavin-containing monooxygenase (FMO) for use in the treatment of cancer

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Integrated valved pipeline and preparation method thereof

The invention discloses an integrated valvular catheter and a preparation method thereof, relates to the technical field of medical instruments, and aims to solve the problems that in a traditional valvular catheter operation, suturing is tedious, tearing and thrombus risks exist, and adaptability is insufficient. The integrated valve-containing pipeline is composed of a valve leaflet and a pipeline body which are integrated through the sintering effect, sewing is not needed, and the reflux and thrombus risks caused by sewing gaps are effectively avoided; a metal memory alloy support is embedded in the wall of the pipeline, so that support can be provided for the valved pipeline to stabilize haemodynamics and prevent the pipeline from collapsing, endovascular intervention delivery can be achieved, and the device is adaptive to a surgical opening mode or an endovascular implantation mode and is used for replacing the valved pipeline at parts such as pulmonary artery and lower limb deep vein of a human body and recovering the function of the damaged valve.
Owner:NANKAI UNIV

Tapping device for clearance of respiratory tract after cardiac surgery

InactiveCN120284695AVibration massageAirway clearanceAirbag
The percussion device comprises a sleeve, a front end cover, a rear end cover, an air bag, a spring, a piston, a piston rod and a permanent magnet, the front end cover and the rear end cover are arranged at the end of the sleeve, the air bag is arranged at one end of the piston rod, the piston rod penetrates through the piston, the spring is arranged between the air bag and the piston and arranged on the piston rod in a sleeving mode, and the permanent magnet is arranged in the sleeve. The permanent magnet is arranged on the face, away from the air bag, of the piston, the electromagnetic coil and the pressure sensor are arranged on the rear end cover, the cushion pad is arranged on the contact face of the pressure sensor, and when the piston rod moves towards the rear end cover, the end, pointing to the rear end cover, of the piston rod makes contact with the cushion pad. The piston rod pushes the head of the airbag to penetrate through the front end cover. Therefore, the damping system can be matched with the resonance frequency of the lung of the human body to enhance the sputum excretion efficiency, effective sputum excretion is guaranteed, rib injuries are avoided, and the clinical applicability and portability are improved.
Owner:ZHONG SHAN PEOPLES HOSPITAL

Application of fusion gene RPL17-C18orf32 as benzo [g, h, i] perylene acute exposure biomarker

The invention discloses an application of a fusion gene RPL17-C18orf32 as a benzo [g, h, i] perylene acute exposure marker, an in-vitro benzo [g, h, i] perylene acute exposure human lung bronchial epithelial cell model is established, abnormal expression of the fusion gene RPL17-C18orf32 is detected, and RPL17-C18orf32 participates in benzo [g, h, i] perylene acute exposure marker expression. The processes of cell proliferation capacity decline, apoptosis rate increase, cycle disorder, cell DNA damage and the like caused by acute exposure of benzo [g, h, i] perylene, so that the fusion gene RPL17-C18orf32 can be used as a biomarker for acute exposure of benzo [g, h, i] perylene. The invention not only provides a potential biomarker for early diagnosis for evaluating the acute exposure of the benzo [g, h, i] perylene, but also provides a new strategy for developing diseases related to the acute exposure of the benzo [g, h, i] perylene for preventing and treating the acute exposure of the benzo [g, h, i] perylene.
Owner:Guangdong Provincial Center for Disease Control and Prevention (Guangdong Academy of Preventive Medicine Sciences) +1

EGFR-TKI drug-resistant human lung adenocarcinoma HCC827 cell strain, kit and application thereof

The invention discloses an EGFR-TKI drug-resistant human lung adenocarcinoma HCC827 cell strain, a kit and application of the EGFR-TKI drug-resistant human lung adenocarcinoma HCC827 cell strain. The cell strain is a human lung cancer cell with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2024221, and is named as Osi-R-HCC827-Pa. The Osi-R-HCC827-Pa and the kit thereof have relatively high application values in screening of drugs for treating the drug resistance of the non-small cell lung cancer and evaluation of the drugs for treating the drug resistance of the non-small cell lung cancer.
Owner:南通药明康德医药科技有限公司

Endobronchial tool training device and associated methods

An endobronchial tool training device may include a simulated human lung main airway network, and at least one training cartridge removably coupled to the simulated human lung main airway network. The training cartridge may include a body of simulated lung tissue having at least one simulated abnormality, and a simulated human lung branch airway network. An endobronchial tool is steerable through the simulated human lung main airway network and into the simulated human lung branch airway network to a position adjacent at least one simulated abnormality.
Owner:INTUITIVE SURGICAL OPERATIONS INC

High-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof

The invention relates to a high-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof, the cell line is named as a human lung adenocarcinoma brain metastasis cell line A549-F3, the cell line is preserved in China Center for Type Culture Collection on March 31, 2025, and the preservation number is CCTCC NO: C2025107. The A549-F3 cell line with high invasiveness and stable brain metastasis characteristics is successfully constructed through an in-vivo circulation screening method, the defects of an existing cell line in lung adenocarcinoma brain metastasis research are overcome, and a more suitable cell model is provided for deep exploration of related mechanisms.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

A butyl tin-cyclometalated iridium phenylpyridine complex with AIE characteristics, and a preparation method and application thereof

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.
Owner:QUFU NORMAL UNIV

A method of constructing a lung organoid that spontaneously generates blood vessels and has a branched morphology

PendingCN122278749AVascularizesBlood vessel
This invention discloses a method for constructing lung organoids with spontaneous vascularization and branching morphology. By optimizing the culture protocol and progressively inducing directional mesoderm, vascularized foregut endoderm, vascularized lung bud organoids, and vascularized lung organoids, lung organoids with both vascularization and branching morphology are successfully cultured, thus more realistically simulating the structural characteristics of the human lung. This invention has significant advantages: First, it can effectively induce the formation of vascularization and branching structures in lung organoids, overcoming the shortcomings of traditional lung organoids that lack vascularization and branching structures; second, by adjusting the culture method in the early stages, the uniformity of the lung organoids is significantly improved, enhancing the reliability and reproducibility of experimental results. This invention provides a more precise and efficient experimental platform for preclinical studies such as lung disease research, drug screening, and toxicology testing, and has significant application value.
Owner:SHANGHAI TONGJI HOSPITAL +1

Triple co-culture cell model for respiratory function research as well as construction method and application of triple co-culture cell model

The invention belongs to the technical field of cell biology, and particularly relates to a triple co-culture cell model for respiratory function research as well as a construction method and application of the triple co-culture cell model. Based on BEAS-2B, THP-1 and MRC-5 cells, a triple co-culture cell model is constructed by adopting a Transwell three-dimensional construction mode, and a complex cell interaction environment after human respiratory tract tissues are exposed to harmful factors such as heavy metals and the like can be simulated. The constructed model is closer to a real physiological anatomical structure in structure, and the multicellular synergistic toxic reaction caused by heavy metal exposure is more comprehensively reproduced in a functional level; an integrated in-vitro model which is closer to human lung tissue in structure, covers multi-stage reaction in function, is standard and stable in operation and has multi-dimensional analysis capability in mechanism is realized for the first time, scientificity, sensitivity and practical applicability of research on respiratory system toxicity caused by heavy metal are remarkably improved, and the method has relatively high technical advancement and industrial transformation potential.
Owner:NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH & POISON CONTROL CHINESE CENTRE FOR DISEASE CONTROL & PREVENTION

Hybrid compounds of sclareol and doxorubicin, their synthesis and application

PendingUS20260174860A1Pharmaceutical active ingredientsMembrane TransportersHybrid compound
The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.
Owner:INSTITUTE FOR BIOLOGICAL RESEARCH SINISA STANKOVIC - NATIONAL INSTITUTE OF THE REPUBLIC OF SERBIA

A wupyv infection model, and a method for constructing the same and use thereof

The application discloses a WUPyV infection model and a construction method and application thereof, and the construction method comprises the following steps: (1) culturing proximal differentiated lung organoids; (2) removing collagen from the lung organoids to prepare lung organoid ball suspension, mixing the lung organoid ball suspension with a WUPyV sample, and co-incubating and infecting; and (3) re-embedding the lung organoids in basement glue after infection, and continuing to culture in a basic culture medium to obtain the WUPyV infection model. The WUPyV infection model is constructed by using three-dimensional human lung organoids, WUPyV can be separated and cultured, the infection process of WUPyV in human lung organs can be better simulated and characterized, and a new infection model is provided for WUPyV infection pathogenesis and body innate immune response mechanism and interaction between viruses and host cells.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Microfluidic system for simulating lung tissue

ActiveCN114867839BLung tissueDrug efficiency
This invention discloses a biomimetic system simulating lung tissue, its manufacturing method, and a method for controlling microfluidics using this biomimetic system. The biomimetic system comprises lung epithelial cells, lung fibroblasts, and human umbilical vein endothelial cells isolated from human lungs, and is perfused with microfluidics. Gas and a fluid including culture medium can be perfused into the internal chambers of the system, simulating similar respiratory movements. Even after more than a week following perfusion, the three types of cells within the system can survive. Furthermore, pH and pO2 within the chambers can be monitored using pH and gas partial pressure sensors within the system, allowing the three types of cells to be exposed to the external environment or drugs under conditions similar to those of a living lung. This enables research in a wide range of fields, including modeling lung diseases caused by harmful substances and testing the efficacy of therapeutic drugs. It is also applicable to in vitro disease modeling and customized drug formulation.
Owner:SEOUL NAT UNIV HOSPITAL

Biodegradable lung sealants

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
Owner:ETHICON INC

Ex VIVO cellular model system comprising heterogenous cells from human lung tumor for the evaluation of drug cytotoxicity in vitro and method thereof

The invention is a model of research and methodology to explore the treatment options for a particular case of lung cancer as an adjuvant therapy after surgical removal of a lung tumor. In practice, the excised / removed tumor is usually examined in the pathology laboratory for revision of the diagnosis, but no functional testing is performed for its sensitivity to subsequent adjuvant 5 therapy. In addition, the tumor is disposed of as unnecessary waste. Our proposal is that the tumor remains should be harvested for cellular studies and, using the model and methodology developed and described herein, preliminary answers can be obtained within 2-3 weeks, predicting which chemotherapeutic agents are likely to have a stronger effect and which therapy is likely to be ineffective for an individual lung cancer patient.
Owner:VILNIUS UNIV

System and composition of respiratory organoids for progagation of viruses and methods thereof

The disclosure is generally directed to a composition, method and system of respiratory organoids that sustain propagation of respiratory pathogens. Also provided is a method of modeling a biological process in a human lung. Also provided is a method of screening for compounds that affect respiratory pathogens in a respiratory organoid model.
Owner:CENTRE FOR VIROLOGY VACCINOLOGY AND THERAPEUTICS LIMITED +1

Application of METTL3 in the preparation of drugs for preventing and treating radiation-induced lung injury

The present invention relates to the application of METTL3 in the preparation of drugs for preventing and treating radiation-induced lung injury. The present invention discovers that METTL3 knockdown has a preventive and therapeutic effect on radiation injury of human lung cells and lung tissues in animal models, can inhibit the epithelial-mesenchymal transition process during the occurrence and development of radiation-induced lung injury, and enhance the antioxidant and post-radiation cell proliferation abilities of lung cells. Therefore, the preventive and therapeutic drugs of the present invention are designed with METTL3 as the target gene, and have important significance and application value in dealing with nuclear and radiation accidents, nuclear emergencies, and reducing the lung radiation injury of tumor radiotherapy patients, etc.
Owner:SUZHOU UNIV

Biomarker for diagnosing pulmonary fibrosis and application thereof

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application thereof, and belongs to the technical field of clinical medicine. The pulmonary fibrosis biomarker lncRNA DLEU2 provided by the invention can effectively assist in diagnosing patients with pulmonary fibrosis, and activation of human lung fibroblasts can be effectively inhibited in the human lung fibroblasts through a knock-down agent sh-DLEU2.
Owner:GUIZHOU PROVINCIAL PEOPLES HOSPITAL